Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10089
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLoveland, Bruce E-
dc.contributor.authorZhao, Anne-
dc.contributor.authorWhite, Shane C-
dc.contributor.authorGan, Hui K-
dc.contributor.authorHamilton, Kate-
dc.contributor.authorXing, Pei-Xiang-
dc.contributor.authorPietersz, Geoffrey A-
dc.contributor.authorApostolopoulos, Vasso-
dc.contributor.authorVaughan, Hilary A-
dc.contributor.authorKaranikas, Vaios-
dc.contributor.authorKyriakou, Peter-
dc.contributor.authorMcKenzie, Ian F C-
dc.contributor.authorMitchell, Paul L R-
dc.date.accessioned2015-05-15T23:25:54Z
dc.date.available2015-05-15T23:25:54Z
dc.date.issued2006-02-01-
dc.identifier.citationClinical Cancer Research; 12(3 Pt 1): 869-77en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10089en
dc.description.abstractTumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous dendritic cells pulsed with mannan-MUC1 fusion protein (MFP) to treat patients with advanced malignancy.Eligible patients had adenocarcinoma expressing MUC1, were of performance status 0 to 1, with no autoimmune disease. Patients underwent leukapheresis to generate dendritic cells by culture ex vivo with granulocyte macrophage colony-stimulating factor and interleukin 4 for 5 days. Dendritic cells were then pulsed overnight with MFP and harvested for reinjection. Patients underwent three cycles of leukapheresis and reinjection at monthly intervals. Patients with clinical benefit were able to continue with dendritic cell-MFP immunotherapy.Ten patients with a range of tumor types were enrolled, with median age of 60 years (range, 33-70 years); eight patients were of performance status 0 and two of performance status 1. Dendritic cell-MFP therapy led to strong T-cell IFNgamma Elispot responses to the vaccine and delayed-type hypersensitivity responses at injection sites in nine patients who completed treatments. Immune responses were sustained at 1 year in monitored patients. Antibody responses were seen in three patients only and were of low titer. Side effects were grade 1 only. Two patients with clearly progressive disease (ovarian and renal carcinoma) at entry were stable after initial therapy and went on to further leukapheresis and dendritic cell-MFP immunotherapy. These two patients have now each completed over 3 years of treatment.Immunization produced T-cell responses in all patients with evidence of tumor stabilization in 2 of the 10 advanced cancer patients treated. These data support further clinical evaluation of this dendritic cell-MFP immunotherapy.en
dc.language.isoenen
dc.subject.otherAdenocarcinoma.immunology.therapyen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAntigens, Neoplasmen
dc.subject.otherCancer Vaccines.administration & dosage.immunology.toxicityen
dc.subject.otherDendritic Cells.immunology.transplantationen
dc.subject.otherDose-Response Relationship, Immunologicen
dc.subject.otherEnzyme-Linked Immunosorbent Assayen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherImmunization Scheduleen
dc.subject.otherImmunotherapyen
dc.subject.otherInterferon-gamma.immunology.secretionen
dc.subject.otherLeukapheresisen
dc.subject.otherMaleen
dc.subject.otherMannans.administration & dosage.immunology.toxicityen
dc.subject.otherMiddle Ageden
dc.subject.otherMucin-1en
dc.subject.otherMucins.administration & dosage.immunologyen
dc.subject.otherPhenotypeen
dc.subject.otherRecombinant Fusion Proteins.administration & dosage.immunologyen
dc.subject.otherT-Lymphocytes.immunologyen
dc.subject.otherTreatment Outcomeen
dc.titleMannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Cancer Researchen
dc.identifier.affiliationAustin Research Institute, and Medical Oncology Unit, Austin Hospital, Heidelberg, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1158/1078-0432.CCR-05-1574en
dc.description.pages869-77en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16467101en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherGan, Hui K
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptNutrition and Dietetics-
crisitem.author.deptIntensive Care-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Apr 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.